Table 1.
β-TM patient characteristics.
| β-TM patients (n = 105) | |
|---|---|
| Age (years) | 22 ± 6.1 |
| Female sex, n (%) | 52 (49.5) |
| BMI (kg/m2) | 20.5 ± 2.5 |
| β-TM mutation types in descending order | IVS1-1/IVS1-1, IVS 1–110/IVS1-110, IVS1-6/IVS1-6, N37/N37, N39/39 |
| History of splenectomy | |
| Yes, n (%) | 59 (56.2) |
| No, n (%) | 46 (43.8) |
| β-TM-associated complications | |
| Cardiomyopathy, n (%) | 15 (14.3) |
| Endocrinopathy, n (%) | 38 (36.2) |
| Transfusion-related characteristics | |
| Transfusion frequency | Once every 2–3 weeks |
| PRBC units per year | 21 ± 4.1 |
| Blood group | |
| O, n (%) | 49 (46.7) |
| A, n (%) | 34 (32.3) |
| B, n (%) | 16 (15.3) |
| AB, n (%) | 6 (5.7) |
| Laboratory measurements | |
| PtHb (g/dl)–SP | 7.2 ± 0.8 |
| PtHb (g/dl)–NSP | 6.8 ± 1.0 |
| TSAT (%) | 90.8 ± 6.8 |
| Ferritin (ng/ml) | 5577 ± 3015 |
| Iron (μg/dl) | 195 ± 510 |
| CRP (mg/dl) | 0.8 ± 0.8 |
| Normal Laboratory References | |
| Hb (g/dl) | Female ≥12/Male ≥13 |
| TSAT (%) | 20.0–45.0 |
| Ferritin (ng/ml) | 24.0–336.0 |
| Iron (μg/dl) | 60.0–170.0 |
| CRP (mg/dl) | ≤0.6 |
| SARS-CoV-2 IgG Antibody titers (AU/ml) | ≥50 |
Data are presented as means ± SD or proportions n with corresponding percentages (%). For some variables, the [normal range] was added to the table.
Abbreviations: BMI, body mass index; β-TM, β-thalassemia major; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; Hb, haemoglobin; NSP, non-splenectomised; PRBC, packed red blood cells; PtHb, pretransfusion haemoglobin; SP, splenectomised; TSAT, transferrin saturation.